Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Subject to certain exceptions and limitations, Novo Nordisk reimburses us for costs and expenses we incur under the Transition Services Agreement, including third-party costs and expenses, costs associated with delivery of transition services by Omeros personnel on an hourly basis at rates specified in the Transition Services Agreement, and for our inventories of zaltenibart drug substance and product.”
FILING10-K0001437749-26-010636cik 0001285819disclosed by OMER
“We are responsible for providing clinical supply of LX9851 to Novo Nordisk at an agreed upon transfer price for a specified time period, following which Novo Nordisk will be responsible for all manufacturing and supply activities for LX9851.”
FILING10-K0001062822-26-000050cik 0001062822disclosed by LXRX
“In February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use, and commercialize products for the prevention, treatment, control, mitigation, or palliation of human or animal diseases or conditions.”
FILING10-K0001641489-26-000010cik 0001641489disclosed by VTVT
“For example, in November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk A/S ("Novo Nordisk"), pursuant to which we granted Novo Nordisk an exclusive worldwide license to our TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases.”
FILING20-F0001193125-26-046590cik 0001612042disclosed by ASND
“In November 2019, we entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive”
FILINGS-1/A0001193125-26-193885cik 0002114044disclosed by COAG
“Novo Nordisk A/S is a shareholder and has entered into three licensing agreements with the Company for the drug candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, the Company will pay milestones and royalties on sales of these drug candidates.”
FILING20-F0001598599-26-000005cik 0001598599disclosed by IPHA
Watchlist prices, news filtered to it, and its next report on your desk.
Novo Nordisk A S
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 42.53 · gapped above the open, then crossed back over prior close. High/low 43.14 at 6:30 am ET, 42.45 at 3:30 pm ET.
Novo Nordisk A S has 3 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Novo Nordisk A S’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NVO (Novo Nordisk A S) has 3 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ASND −9.60%, in healthcare.